クリグルファーマ株式会社

news

Aug 31, 2020Notice

Kringle Pharma and Maruishi Pharmaceutical enter into a capital and business partnership for KP-100IT in acute spinal cord injury.

PDF
Jul 20, 2020Notice

Kringle initiates Phase 3 clinical trial of recombinant human HGF for the treatment of acute spinal cord injury.

PDF
Jun 19, 2020Notice

Kringle Pharma announces that positive clinical results from Phase I/II trial of recombinant human HGF, KP-100IT, in subjects with acute spinal cord injury were published in the peer-reviewed Journal of Neurotrauma (Published Online: 22 May 2020, DOI: 10.1089/neu.2019.6854).

Apr 7, 2020Notice

Kringle Pharma additionally raises 740 million Japanese yen toward commercialization of recombinant human HGF drug.

PDF
Mar 2, 2020Notice

Kringle Pharma successfully raises 950 million Japanese yen to advance clinical development of recombinant human HGF.

PDF
Mar 2, 2020Notice

Kringle Pharma and Toho Holdings enter into a capital and business alliance for KP-100IT in acute spinal cord injury.

PDF